Log In
Print
BCIQ
Print
Print this Print this
 

ProstVac, rilimogene galvacirepvec

Also known as: ProstVac-VF

  Manage Alerts
Collapse Summary General Information
Company Bavarian Nordic A/S
DescriptionVaccine targeting PSA that also contains a Tricom triad of costimulatory molecules -- CD58 (LFA-3), intercellular adhesion molecule-1 (ICAM-1; CD54) and CD80 (B7-1)
Molecular Target Prostate-specific antigen (KLK3) (PSA)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsTreat androgen-independent castration-resistant prostate cancer (CRPC); Treat castration-resistant prostate cancer (CRPC) with bone metastases; Treat hormone-dependent prostate cancer; Treat localized prostate cancer; Treat metastatic castration-resistant prostate cancer (CRPC); Treat metastatic prostate cancer; Treat non-metastatic castration-sensitive prostate cancer; Treat prostate cancer; Treat prostate cancer in hormone-naïve patients
Regulatory Designation U.S. - Fast Track (Treat metastatic castration-resistant prostate cancer (CRPC));
U.S. - Special Protocol Assessment (Treat metastatic castration-resistant prostate cancer (CRPC))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$975.0M

0

$835.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today